MRG 002
Alternative Names: MRG-002Latest Information Update: 28 Apr 2024
At a glance
- Originator Miracogen
- Developer Lepu Biopharma; Miracogen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Urogenital cancer
- Phase II/III HER2 positive breast cancer
- Phase II Biliary cancer; Breast cancer; Gastric cancer
- Phase I/II Oesophageal cancer; Solid tumours
- No development reported Colorectal cancer; Salivary gland cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Salivary-gland-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)